Nicholas M. Dean

Executive Officer at Providence Therapeutics, Inc.

Nicholas M. Dean

Nicholas M. Dean

Executive Officer at Providence Therapeutics, Inc.

Overview
Career Highlights

Ionis Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc.

RelSci Relationships

144

Number of Boards

4

Birthday

1958

Age

60

Relationships
RelSci Relationships are individuals Nicholas M. Dean likely has professional access to. A relationship does not necessarily indicate a personal connection.

Senior Vice President, Manufacturing & Supply Chain at Boston Scientific Corporation

Relationship likelihood: Strong

Executive Chairman at Redwood Bioscience, Inc.

Relationship likelihood: Strong

R&D & Medical Consultant at Arcturus Therapeutics, Inc.

Relationship likelihood: Strong

Founder, Chief Executive Officer & Chairman of the Board of Directors at Dermira, Inc.

Relationship likelihood: Strong

Professor, Medicine at University of Pennsylvania - Perelman School of Medicine

Relationship likelihood: Strong

Chief Financial Officer & Secretary at biOasis Technologies, Inc.

Relationship likelihood: Strong

Managing Director at RiverVest Venture Management LLC

Relationship likelihood: Strong

Executive Chairman, Chief Executive Officer & Chief Financial Officer at Sydys Corp.

Relationship likelihood: Strong

Executive Officer at Providence Therapeutics, Inc.

Relationship likelihood: Strong

Managing Director at RiverVest Venture Management LLC

Relationship likelihood: Strong

Paths to Nicholas M. Dean
Potential Connections via
Relationship Science
You
Nicholas M. Dean
Executive Officer at Providence Therapeutics, Inc.
Education
Doctorate

ght into being through the determination, enthusiasm for learning, and generosity of ordinary Welsh people, the establishment of the University of Wales by Royal Charter in 1893 was regarded as one of the most important political and social developments in the nineteenth century. The University of Wales has a long and proud history, playing an important role in the development of higher education in Wales. Through the University’s support for the Centre for Advanced Welsh and Celtic Studies (CAWCS), Geiriadur Prifysgol Cymru (The Welsh Dictionary), Gregynog Hall (bequeathed to the University in the 1960’s) and the University of Wales Press, it helped to promote and celebrate the language, heritage and culture of Wales.

Ph.D. in Pharmacology

Cardiff University School of Medicine is a school in Cardiff.

Career History
Executive Officer
Current
Founder
2006 - 2012

Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY.

Executive Director & Vice President, Functional Genomics & Oncology
1991 - Prior

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates its business through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke on January 10, 1989 and is headquartered in Carlsbad, CA.

Boards & Committees
Member, Scientific Advisory Board
Prior - 2015

Arcturus Therapeutics, Inc. engages in the development of technology and therapeutics for rare diseases. It specializes in the application of application of ribonucleic acid technologies for the treatment of disease. The company was founded by Joseph E. Payne and Padmanabh Chivukula in 2013 and is headquartered in San Diego, CA.

Director & Chief Scientific Officer
2006 - 2012

Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY.

Director & Chief Scientific Officer
Prior

Microlin Bio, Inc. is a pre-clinical stage biopharmaceutical company. It focuses on the development of miR-based diagnostics and therapeutics, including both antimiRs and miR mimics, to diagnose and treat cancer. The company was founded by Joseph Hernandez on July 30, 2013 and is headquartered in New York, NY.

Transactions
Details Hidden

Providence Therapeutics, Inc. raised money in a private placement transaction

Investments
Details Hidden

Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY.